Listed

BridgeBio Pharma, Inc.: Form 10-Q for the period ended Jun 30, 2020

Filed with the SEC on Aug 11, 2020 and accepted by EDGAR at Aug 11, 2020, 17:18 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-04-01 to 2020-06-30$86.6mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2020-01-01 to 2020-06-30$154.8mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-04-01 to 2020-06-30−$124.6mus-gaap:OperatingIncomeLoss
Operating income6 months2020-01-01 to 2020-06-30−$227.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-04-01 to 2020-06-30$10.8mus-gaap:InterestExpense
Interest expense6 months2020-01-01 to 2020-06-30$14.8mus-gaap:InterestExpense
Net income3 months2020-04-01 to 2020-06-30−$136.2mus-gaap:ProfitLoss
Net income6 months2020-01-01 to 2020-06-30−$240.3mus-gaap:ProfitLoss
Diluted EPS3 months2020-04-01 to 2020-06-30−$1.03us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2020-01-01 to 2020-06-30−$1.81us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2020-01-01 to 2020-06-30−$171.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2020-01-01 to 2020-06-30$4.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases6 months2020-01-01 to 2020-06-30$75.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-06-30$540.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-06-30$861.9mus-gaap:AssetsCurrent
Total assetsAt period end2020-06-30$905.2mus-gaap:Assets
Current liabilitiesAt period end2020-06-30$92.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-06-30$577.7mus-gaap:Liabilities
Long-term debtAt period end2020-06-30$92.9mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2020-06-30$265.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-20-039358. Last ingested by Listed: Nov 12, 2026, 17:56 ET. Listed shows no prices and gives no investment advice.